KEGG   DRUG: Satralizumab
Entry
D11079                      Drug                                   
Name
Satralizumab (USAN/INN);
Satralizumab (genetical recombination) (JAN);
satralizumab-mwge;
Enspryng (TN)
Product
ENSPRYNG (Genentech)
Formula
C6340H9776N1684O2022S46
Exact mass
143326.1068
Mol weight
143414.519
Sequence
(Heavy chain)
QVQLQESGPG LVKPSETLSL TCAVSGHSIS HDHAWSWVRQ PPGEGLEWIG FISYSGITNY
NPSLQGRVTI SRDNSKNTLY LQMNSLRAED TAVYYCARSL ARTTAMDYWG EGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK SCVECPPCPA PPVAGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQEGNV
FSCSVMHEAL HAHYTQKSLS LSP
(heavy chain)
QVQLQESGPG LVKPSETLSL TCAVSGHSIS HDHAWSWVRQ PPGEGLEWIG FISYSGITNY
NPSLQGRVTI SRDNSKNTLY LQMNSLRAED TAVYYCARSL ARTTAMDYWG EGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK SCVECPPCPA PPVAGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQEGNV
FSCSVMHEAL HAHYTQKSLS LSP
(Light chain)
DIQMTQSPSS LSASVGDSVT ITCQASTDIS SHLNWYQQKP GKAPELLIYY GSHLLSGVPS
RFSGSGSGTD FTFTISSLEA EDAATYYCGQ GNRLPYTFGQ GTKVEIERTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(light chain)
DIQMTQSPSS LSASVGDSVT ITCQASTDIS SHLNWYQQKP GKAPELLIYY GSHLLSGVPS
RFSGSGSGTD FTFTISSLEA EDAATYYCGQ GNRLPYTFGQ GTKVEIERTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H146-H202, H222-L214, H225-h225, H228-h228, H259-H319, H365-H423, h22-h96, h146-l202, h222-l214, h259-h319, h365-h423, L23-L88, L134-L194, l23-l88, l134-l194)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 6399
ATC code: L04AC19
Product: D11079<JP/US>
Efficacy
Anti-inflammatory, Immunosuppressant, Anti-IL-6 receptor antibody
  Disease
Neuromyelitis optica spectrum disorder (anti-AQP4 antibody positive) [DS:H01491]
  Type
Monoclonal antibody
Comment
Treatment of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMO-SD)
Target
IL6R (CD126) [HSA:3570] [KO:K05055]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC19 Satralizumab
      D11079  Satralizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Ophthalmic Agents
  Ophthalmic Agents, Other
   Satralizumab
    D11079  Satralizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11079  Satralizumab (USAN/INN); Satralizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11079  Satralizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11079  Satralizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL6R (CD126)
     D11079  Satralizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11079
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11079
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11079
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11079
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11079
Other DBs
CAS: 1535963-91-7
PubChem: 375581026
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system